Emergent BioSolutions’ (Booth 1240) Emergard has been selected by the U.S. Department of Defense (DoD) and Battelle to be tested against and developed to U.S. military specifications as a platform for nerve agent antidote delivery. Emergard is a rugged, military-grade auto-injector platform designed to be transported, stored, and operated in a military environment and to ensure needle penetration and successful injection through chemical protective gear. Development and testing of Emergard is expected to be completed in 2016.
 
“We are pleased that our Emergard platform has been selected by DoD and Battelle for development to address U.S. military auto-injector needs,” said Adam Havey, executive vice president and president, biodefense division of Emergent BioSolutions. “The Emergard platform, which is designed for intramuscular self-injection of antidotes and other emergency response medical treatments for nerve agents and other chemical threats, is another example of Emergent’s commitment to protecting lives and being a global leader in the development and manufacture of medical countermeasures that address biological and chemical threats as well as emerging infectious diseases.”
 
The testing and development of Emergard will be performed under a subcontract with Battelle, which has a prime contract with DoD. This contract is supported by the Defense Technical Information Center, which serves the DoD community.